Medical instruments provider Civco has completed the acquisition of Barzell-Whitmore Maroon Bells, a designer and manufacturer of specialized positioning and stabilizing devices used in image-guided minimally invasive surgery. The
Medical instruments provider Civco has completed the acquisition of Barzell-Whitmore Maroon Bells, a designer and manufacturer of specialized positioning and stabilizing devices used in image-guided minimally invasive surgery. The subsidiary of Colorado MedTech made the purchase with 127,000 shares of MedTech stock and $2 million in cash at closing. An additional $2.2 million will be paid if certain performance standards are met. Annualized revenues associated with the acquisition are expected to be about $2 million. Barzell-Whitmore's devices are used in evaluation of colorectal disease and the treatment of prostate cancer. Expected future applications will involve laparoscopic surgery and the treatment of benign prostate hyperplasia. The acquisition will expand the portfolio of Civco products used to perform image-guided procedures.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.